

## 1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : Afatinib

Product Number : 10-4510

Brand : Focus Biomolecules

CAS-No. : 850140-72-6

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For Laboratory Research Use Only

1.3 Details of the supplier of the safety data sheet

Company : Focus Biomolecules

400 Davis Drive, Suite 600 Plymouth Meeting, PA 19462

Telephone : +1 855-362-8721

E-mail : support@focusbiomolecules.com

1.4 Emergency telephone number

Emergency Phone # : CHEMTREC within USA/Canada 1-800- 424-9300

CHEMTREC outside USA/Canada 1-703-527-3887

## 2. HAZARDS IDENTIFICATION

## 2.1 Classification of the substance or mixture

# GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Acute Toxicity Oral (Category 4), H302

For the full text of the H-Statements mentioned in this Section, see Section 16. GHS

# Label elements, including precautionary statements

2.2 Pictogram



Signal word Warning

Hazard statement(s) H315

H302 Harmful if swallowed.

Precautionary statement(s)

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink, or smoke when using this product

P301 + P312 IF SWALLOWED: Call a POISON CONTROL CENTER or doctor/physician

if you feel unwell.

P330 Rinse mouth

P501 Dispose of contents/container to an approved waste disposal plant

Afatinib Page 1 of 7

## 2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### 3.1 Substances

Synonyms: N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-

quinazolinyl]-4(dimethylamino)-2E-butenamide: BIBW2992

Formula :  $C_{24}H_{25}CIFN_5O_3$ Molecular Weight : 485.94 g/mol CAS-No. : 850140-72-6

**Hazardous components** 

Component	Classification	Concentration
Afatinib		
	Acute Tox Oral (Cat 4);	-
	H302	

For the full text of the H-Statements mentioned in this Section, see Section 16.

### 4. FIRST AID MEASURES

## 4.1 Description of first aid measures

## **General advice**

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

#### If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

#### In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

# In case of eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

#### If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

# 4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

# 4.3 Indication of any immediate medical attention and special treatment needed

no data available

## 5. FIREFIGHTING MEASURES

# 5.1 Extinguishing media

## Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

# 5.2 Special hazards arising from the substance or mixture

Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride

## 5.3 Advice for firefighters

Wear self contained breathing apparatus for fire fighting if necessary.

## 5.4 Further information

no data available

## **6. ACCIDENTAL RELEASE MEASURES**

## 6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Avoid breathing dust.

For personal protection see section 8.

Afatinib Page 2 of 7

# 6.2 Environmental precautions

Do not let product enter drains.

## 6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

#### 6.4 Reference to other sections

For disposal see section 13.

## 7. HANDLING AND STORAGE

## 7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed.

For precautions see section 2.2.

### 7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature: -20 °C

# 7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1 Control parameters

### Components with workplace control parameters

Contains no substances with occupational exposure limit values.

# 8.2 Exposure controls

# Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

# Personal protective equipment

#### Eve/face protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

#### Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

## **Body Protection**

impervious clothing, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

#### Respiratory protection

For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

# Control of environmental exposure

Do not let product enter drains.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

## 9.1 Information on basic physical and chemical properties

a) Appearance Form: solid

Colour: yellow

b) Odour no data available

Afatinib Page 3 of 7

c)	Odour Threshold	no	data	available	
d)	рН	no	data	available	
e)	Melting point/freezing point	no data available			
f)	Initial boiling point and boiling range	no data available			
g)	Flash point	no data available			
h)	Evapouration rate	no data available			
i)	Flammability (solid, gas)	no data available			
j)	Upper/lower flammability or explosive limits	no data available			
k)	Vapour pressure	no data available			
I)	Vapour density	no data available			
m)	Relative density	no data available			
n)	Water solubility	no data available			
o)	Partition coefficient: n-octanol/water	no data available			
p)	Auto-ignition temperature	no data available			
q)	Decomposition temperature	no data available			
r)	Viscosity	no data available			
s)	Explosive properties	no data available			
t)	Oxidizing properties	no data available			
Other safety information					

# 9.2 Other safety information

no data available

# 10. STABILITY AND REACTIVITY

# 10.1 Reactivity

no data available

## 10.2 Chemical stability

Stable under recommended storage conditions.

# 10.3 Possibility of hazardous reactions

no data available

## 10.4 Conditions to avoid

no data available

# 10.5 Incompatible materials

Strong oxidizing agents

# 10.6 Hazardous decomposition products

Other decomposition products - Carbon oxides, nitrogen oxides, hydrogen chloride, hydrogen fluoride In the event of fire: see section

# 11. TOXICOLOGICAL INFORMATION

# 11.1 Information on toxicological effects

# **Acute toxicity**

no data available

Afatinib Page 4 of 7

Inhalation: no data available

Dermal: no data available

no data available

#### Skin corrosion/irritation

no data available

## Serious eye damage/eye irritation

no data available

## Respiratory or skin sensitisation

no data available

## Germ cell mutagenicity

no data available

# Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as

probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a

known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by OSHA.

# Reproductive toxicity

no data available

no data available

## Specific target organ toxicity - single exposure

no data available

# Specific target organ toxicity - repeated exposure

no data available

## **Aspiration hazard**

no data available

### **Additional Information**

RTECS: Not available

Headache, Dizziness, Anorexia., Vomiting, Diarrhoea, Nausea, Fever, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

# 12. ECOLOGICAL INFORMATION

### 12.1 Toxicity

no data available

# 12.2 Persistence and degradability

no data available

# 12.3 Bioaccumulative potential

no data available

# 12.4 Mobility in soil

no data available

# 12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

### 12.6 Other adverse effects

no data available

Afatinib Page 5 of 7

# 13. DISPOSAL CONSIDERATIONS

### 13.1 Waste treatment methods

#### **Product**

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material.

# Contaminated packaging

Dispose of as unused product.

## 14. TRANSPORT INFORMATION

### DOT (US)

Not dangerous goods

#### **IMDG**

Not dangerous goods

### IATA

Not dangerous goods

# 15. REGULATORY INFORMATION

## **SARA 302 Components**

SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

### **SARA 313 Components**

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

## SARA 311/312 Hazards

Acute Health Hazard

# **Massachusetts Right To Know Components**

No components are subject to the Massachusetts Right to Know Act.

# Pennsylvania Right To Know Components

CAS-No. Revision Date

Afatinib 850140-72-6

**New Jersey Right To Know Components** 

CAS-No. Revision Date

Afatinib 850140-72-6

# California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

### 16. OTHER INFORMATION

#### Full text of H-Statements referred to under sections 2 and 3.

H302 Harmful if swallowed

Skin Irrit.

# **HMIS Rating**

Health hazard: 2
Chronic Health Hazard:
Flammability: 0
Physical Hazard 0

Afatinib Page 6 of 7

# **NFPA Rating**

Health hazard: 2
Fire Hazard: 0
Reactivity Hazard: 0

# **Further information**

Copyright 2023 Focus Biomolecules. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Materials are intended for Laboratory Use only and must be used by qualified technicians. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Focus Biomolecules and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Version: 1.0 Revision Date: 05/22/2023

Afatinib Page 7 of 7